SAGE Therapeutics (SAGE) Misses Q3 EPS by 9c

November 8, 2022 6:34 AM EST

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.31), $0.09 worse than the analyst estimate of ($2.22). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities